# OnCo record eflapegrastim (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/eflapegrastim/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "eflapegrastim" ;
  schema:name "Eflapegrastim"@en ;
  schema:alternateName "Eflapegrastim-xnst"@en, "SPI-2012"@en, "Rolvedon" ;
  schema:description "Eflapegrastim is a once-per-cycle white cell growth factor approved in the United States in 2022 to prevent infections when chemotherapy for solid tumours knocks down neutrophils, an alternative to pegfilgrastim."@en ;
  schema:url <https://onco.cc/drugs/eflapegrastim/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Eflapegrastim> ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761148>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=eflapegrastim>, <https://en.wikipedia.org/wiki/Eflapegrastim> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Long-acting G-CSF fused to an antibody Fc fragment, once per chemotherapy cycle" ;
  onco:approval "US 2022: To decrease the incidence of febrile neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:targets <https://onco.cc/targets/csf3r/> ;
  onco:drugs <https://onco.cc/drugs/pegfilgrastim/> ;
  onco:companies <https://onco.cc/companies/spectrum-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct04570423/> .